• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties.

作者信息

Collins P, Chalmers E, Alamelu J, Hay C, Liesner R, Makris M, Mathias M, Payne J, Rangarajan S, Richards M, Talks K, Tunstall O, Williams M, Hart D P

机构信息

Arthur Bloom Haemophilia Centre, University Hospital of Wales, Cardiff, UK.

Haemophilia Centre, Royal Hospital for Children, Glasgow, UK.

出版信息

Haemophilia. 2017 Sep;23(5):654-659. doi: 10.1111/hae.13264. Epub 2017 Jun 2.

DOI:10.1111/hae.13264
PMID:28574205
Abstract
摘要

相似文献

1
First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties.重度甲型血友病患儿的一线免疫耐受诱导：英国血友病中心医生组织抑制剂与儿科工作组的方案
Haemophilia. 2017 Sep;23(5):654-659. doi: 10.1111/hae.13264. Epub 2017 Jun 2.
2
First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.在一项观察性免疫耐受诱导研究中，关于高危血友病A抑制物患者使用单一凝血因子VIII/血管性血友病因子浓缩物的免疫耐受的首份前瞻性报告。
Haemophilia. 2016 Jan;22(1):87-95. doi: 10.1111/hae.12774. Epub 2015 Jul 23.
3
Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.在14例重度甲型血友病患者中使用含血管性血友病因子的凝血因子VIII浓缩剂（Haemoctin SDH®）诱导免疫耐受。
Haemophilia. 2011 Sep;17(5):e837-40. doi: 10.1111/j.1365-2516.2011.02577.x. Epub 2011 Jun 7.
4
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update.严重血友病 A 患者的免疫耐受诱导：英国血友病临床医生组织抑制剂工作组和儿科工作组共识更新。
Haemophilia. 2021 Nov;27(6):932-937. doi: 10.1111/hae.14381. Epub 2021 Aug 17.
5
Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study.在澳大利亚患有高滴度抑制物的儿童重度甲型血友病患者中，使用含或不含免疫抑制的凝血因子 VIII/血管性血友病因子浓缩物（BIOSTATE）诱导免疫耐受：一项多中心回顾性研究。
Thromb Res. 2014 Nov;134(5):1046-51. doi: 10.1016/j.thromres.2014.09.010. Epub 2014 Sep 21.
6
Successful eradication of inhibitor of late recurrence and other high risk prognostic factors in a patient with severe haemophilia A.成功根除一名重度甲型血友病患者晚期复发抑制剂及其他高危预后因素。
Haemophilia. 2011 Sep;17(5):e833-4. doi: 10.1111/j.1365-2516.2011.02571.x. Epub 2011 May 30.
7
Induction of immune tolerance with factor VIII concentrate in patients with hemophilia A and inhibitors.用凝血因子VIII浓缩物诱导甲型血友病伴抑制物患者的免疫耐受。
Prog Clin Biol Res. 1990;324:59-68.
8
The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.在英国，先前未接受治疗的血友病 A 患者使用 ReFacto AF（moroctocog alfa AF-CC）的免疫原性。
Haemophilia. 2018 Nov;24(6):896-901. doi: 10.1111/hae.13551. Epub 2018 Jul 13.
9
How I treat inhibitors in haemophilia.我如何治疗血友病抑制剂。
Haemophilia. 2012 Jul;18 Suppl 4:48-53. doi: 10.1111/j.1365-2516.2012.02829.x.
10
Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors.Fanhdi/Alphanate（血浆源性含血管性血友病因子的凝血因子VIII浓缩物）用于诱导A型血友病伴抑制物患者免疫耐受的临床概述
Haemophilia. 2016 Jan;22(1):e71-4. doi: 10.1111/hae.12857. Epub 2015 Nov 27.

引用本文的文献

1
[Treatment of haemophilia in Austria].[奥地利的血友病治疗]
Wien Klin Wochenschr. 2024 Jul;136(Suppl 4):75-102. doi: 10.1007/s00508-024-02370-0. Epub 2024 May 14.
2
Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study.在观察性免疫耐受诱导（ObsITI）研究中，对100例患者使用pdFVIII/VWF浓缩物（奥曲肽）进行免疫耐受诱导（ITI）。
TH Open. 2022 May 26;6(2):e124-e134. doi: 10.1055/s-0042-1748756. eCollection 2022 Apr.
3
Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.
根据中国血友病A抑制物患儿的预后危险因素，单独或联合免疫抑制剂进行低剂量免疫耐受诱导。
Res Pract Thromb Haemost. 2021 Jul 14;5(5):e12562. doi: 10.1002/rth2.12562. eCollection 2021 Jul.
4
Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study.关于英国血友病抑制剂患者护理标准的专家意见：一项改良的德尔菲共识研究。
Ther Adv Hematol. 2021 Apr 30;12:20406207211007058. doi: 10.1177/20406207211007058. eCollection 2021.
5
Low-dose immune tolerance induction for children with hemophilia A with poor-risk high-titer inhibitors: A pilot study in China.低剂量免疫耐受诱导治疗中国高危高滴度抑制物血友病A患儿的一项试点研究。
Res Pract Thromb Haemost. 2019 Aug 9;3(4):741-748. doi: 10.1002/rth2.12248. eCollection 2019 Oct.
6
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.随着emicizumab 的出现，血友病 A 免疫耐受诱导的面貌正在发生变化。
Haemophilia. 2019 Jul;25(4):676-684. doi: 10.1111/hae.13762. Epub 2019 Apr 29.
7
[Chinese guidelines on the diagnosis and treatment of coagulation factor Ⅷ/Ⅸ inhibitors (version 2018)].《凝血因子Ⅷ/Ⅸ抑制物诊断与治疗中国专家共识（2018年版）》
Zhonghua Xue Ye Xue Za Zhi. 2018 Oct 14;39(10):793-799. doi: 10.3760/cma.j.issn.0253-2727.2018.10.001.
8
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.在甲型或乙型血友病患者中进行和解读个体药代动力学概况：基本原理和一般注意事项。
Res Pract Thromb Haemost. 2018 May 20;2(3):535-548. doi: 10.1002/rth2.12106. eCollection 2018 Jul.
9
Advances and innovations in haemophilia treatment.血友病治疗的进展与创新。
Nat Rev Drug Discov. 2018 Jul;17(7):493-508. doi: 10.1038/nrd.2018.70. Epub 2018 Jun 8.